Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Die Dermatologie
Erschienen in: Der Hautarzt 6/2017

27.04.2017 | Zytokine | CME

Morbus Still im Kindes- und Erwachsenenalter

verfasst von: PD Dr. C. M. Hedrich, C. Günther, M. Aringer

Erschienen in: Die Dermatologie | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die systemische juvenile idiopathische Arthritis (sJIA) ist durch Fieber, Arthritis und weitere Symptome systemischer Inflammation gekennzeichnet. Historisch ist sie nach ihrem Erstbeschreiber George Frederic Still als Morbus Still benannt. Tritt die Erkrankung bei Erwachsenen auf, wird sie als adulte Still-Erkrankung („adult onset Still’s disease“, AOSD) bezeichnet. Die Pathophysiologie der sJIA und der AOSD wird inkomplett verstanden. Die gesteigerte Aktivierung von Inflammasomen und die Expression proinflammatorischer Zytokine spielen eine zentrale Rolle. S100-Proteine, die durch die Aktivierung von Toll-like-Rezeptoren als positiver Verstärker wirken, sind ebenso erhöht im Serum von sJIA-Patienten messbar. Reduzierte Produktion des immunmodulatorischen Zytokins IL-10 könnte zudem zur Aktivierung von Immunzellen und der Produktion inflammatorischer Botenstoffe beitragen. In diesem Beitrag werden die klinische Präsentation, die Differenzialdiagnostik, der aktuelle Wissensstand zur Pathophysiologie sowie Therapieoptionen der sJIA und der AOSD diskutiert.
Literatur
1.
Bruck N, Schnabel A, Hedrich CM (2015) Current understanding of the pathophysiology of systemic juvenile idiopathic arthritis (sJIA) and target-directed therapeutic approaches. Clin Immunol 159(1):72–83CrossRefPubMed
2.
Hedrich CM, Bruck N, Fiebig B, Gahr M (2012) Anakinra: a safe and effective first-line treatment in systemic onset juvenile idiopathic arthritis (SoJIA). Rheumatol Int 32(11):3525–3530CrossRefPubMed
3.
Calabro JJ, Marchesano JM (1968) Rash associated with juvenile rheumatoid arthritis. J Pediatr 72(5):611–619CrossRefPubMed
4.
Sunderkotter C, Frieling U, Nashan D, Metze D (1998) Adult-onset Still’s disease and its characteristic rash. Hautarzt 49(12):920–924CrossRefPubMed
5.
Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Seve P (2014) Adult-onset Still’s disease. Autoimmun Rev 13(7):708–722CrossRefPubMed
6.
Correll CK, Binstadt BA (2014) Advances in the pathogenesis and treatment of systemic juvenile idiopathic arthritis. Pediatr Res 75(1–2):176–183CrossRefPubMed
7.
8.
9.
Mellins ED, Macaubas C, Grom AA (2011) Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol 7(7):416–426CrossRefPubMedPubMedCentral
10.
Behrens EM, Beukelman T, Gallo L et al (2008) Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR). J Rheumatol 35(2):343–348PubMed
11.
Kalyoncu U, Solmaz D, Emmungil H et al (2016) Response rate of initial conventional treatments, disease course, and related factors of patients with adult-onset Still’s disease: data from a large multicenter cohort. J Autoimmun 69:59–63CrossRefPubMed
12.
Cush JJ, Medsger TA Jr., Christy WC, Herbert DC, Cooperstein LA (1987) Adult-onset Still’s disease. Clinical course and outcome. Arthritis Rheum 30(2):186–194CrossRefPubMed
13.
Oen K (2002) Long-term outcomes and predictors of outcomes for patients with juvenile idiopathic arthritis. Best Pract Res Clin Rheumatol 16(3):347–360CrossRefPubMed
14.
Schneider R, Lang BA, Reilly BJ et al (1992) Prognostic indicators of joint destruction in systemic-onset juvenile rheumatoid arthritis. J Pediatr 120(2 Pt 1):200–205CrossRefPubMed
15.
Singh-Grewal D, Schneider R, Bayer N, Feldman BM (2006) Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features. Arthritis Rheum 54(5):1595–1601CrossRefPubMed
16.
17.
Nigrovic PA (2014) Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis? Arthritis Rheumatol 66(6):1405–1413CrossRefPubMed
18.
de Jager W, Hoppenreijs EP, Wulffraat NM, Wedderburn LR, Kuis W, Prakken BJ (2007) Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann Rheum Dis 66(5):589–598CrossRefPubMed
19.
Fall N, Barnes M, Thornton S et al (2007) Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum 56(11):3793–3804CrossRefPubMed
20.
Ogilvie EM, Khan A, Hubank M, Kellam P, Woo P (2007) Specific gene expression profiles in systemic juvenile idiopathic arthritis. Arthritis Rheum 56(6):1954–1965CrossRefPubMed
21.
Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J (2005) Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 201(9):1479–1486CrossRefPubMedPubMedCentral
22.
Nigrovic PA, Mannion M, Prince FH et al (2011) Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 63(2):545–555CrossRefPubMed
23.
Vastert SJ, de Jager W, Noordman BJ et al (2014) Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol 66(4):1034–1043CrossRefPubMed
24.
Verbsky JW, White AJ (2004) Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 31(10):2071–2075PubMed
25.
Barker BR, Taxman DJ, Ting JP (2011) Cross-regulation between the IL-1beta/IL-18 processing inflammasome and other inflammatory cytokines. Curr Opin Immunol 23(5):591–597CrossRefPubMedPubMedCentral
26.
de Jager W, Vastert SJ, Beekman JM et al (2009) Defective phosphorylation of interleukin-18 receptor beta causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 60(9):2782–2793CrossRefPubMed
27.
De Benedetti F, Brunner H, Ruperto N et al (2015) Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: results from a phase III trial. Arthritis Rheumatol 67(3):840–848CrossRefPubMed
28.
de Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A (1991) Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 34(9):1158–1163CrossRefPubMed
29.
De Benedetti F, Meazza C, Oliveri M et al (2001) Effect of IL-6 on IGF binding protein-3: a study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis. Endocrinology 142(11):4818–4826CrossRefPubMed
30.
Jin J, Samuvel DJ, Zhang X et al (2011) Coactivation of TLR4 and TLR2/6 coordinates an additive augmentation on IL-6 gene transcription via p38MAPK pathway in U937 mononuclear cells. Mol Immunol 49(3):423–432CrossRefPubMedPubMedCentral
31.
Foell D, Frosch M, Sorg C, Roth J (2004) Phagocyte-specific calcium-binding S100 proteins as clinical laboratory markers of inflammation. Clin Chim Acta 344(1–2):37–51CrossRefPubMed
32.
Kessel C, Holzinger D, Foell D (2013) Phagocyte-derived S100 proteins in autoinflammation: putative role in pathogenesis and usefulness as biomarkers. Clin Immunol 147(3):229–241CrossRefPubMed
33.
Wittkowski H, Frosch M, Wulffraat N et al (2008) S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum 58(12):3924–3931CrossRefPubMedPubMedCentral
34.
35.
Hofmann SR, Rosen-Wolff A, Tsokos GC, Hedrich CM (2012) Biological properties and regulation of IL-10 related cytokines and their contribution to autoimmune disease and tissue injury. Clin Immunol 143(2):116–127CrossRefPubMed
36.
Hofmann SR, Kubasch AS, Ioannidis C et al (2015) Altered expression of IL-10 family cytokines in monocytes from CRMO patients result in enhanced IL-1beta expression and release. Clin Immunol 161(2):300–307CrossRefPubMed
37.
Hofmann SR, Morbach H, Schwarz T, Rosen-Wolff A, Girschick HJ, Hedrich CM (2012) Attenuated TLR4/MAPK signaling in monocytes from patients with CRMO results in impaired IL-10 expression. Clin Immunol 145(1):69–76CrossRefPubMed
38.
Hofmann SR, Schwarz T, Moller JC et al (2011) Chronic non-bacterial osteomyelitis is associated with impaired Sp1 signaling, reduced IL10 promoter phosphorylation, and reduced myeloid IL-10 expression. Clin Immunol 141(3):317–327CrossRefPubMed
39.
Fife MS, Gutierrez A, Ogilvie EM et al (2006) Novel IL10 gene family associations with systemic juvenile idiopathic arthritis. Arthritis Res Ther 8(5):R148CrossRefPubMedPubMedCentral
40.
Moller JC, Paul D, Ganser G et al (2010) IL10 promoter polymorphisms are associated with systemic onset juvenile idiopathic arthritis (SoJIA). Clin Exp Rheumatol 28(6):912–918PubMed
41.
Stock CJ, Ogilvie EM, Samuel JM, Fife M, Lewis CM, Woo P (2008) Comprehensive association study of genetic variants in the IL-1 gene family in systemic juvenile idiopathic arthritis. Genes Immun 9(4):349–357CrossRefPubMed
42.
Fishman D, Faulds G, Jeffery R et al (1998) The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102(7):1369–1376CrossRefPubMedPubMedCentral
43.
Ogilvie EM, Fife MS, Thompson SD et al (2003) The −174 G allele of the interleukin-6 gene confers susceptibility to systemic arthritis in children: a multicenter study using simplex and multiplex juvenile idiopathic arthritis families. Arthritis Rheum 48(11):3202–3206CrossRefPubMed
44.
De Benedetti F, Meazza C, Vivarelli M et al (2003) Functional and prognostic relevance of the −173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 48(5):1398–1407CrossRefPubMed
45.
Donn RP, Shelley E, Ollier WE, Thomson W, British Paediatric Rheumatology Study Group (2001) A novel 5′-flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 44(8):1782–1785CrossRefPubMed
46.
Meazza C, Travaglino P, Pignatti P et al (2002) Macrophage migration inhibitory factor in patients with juvenile idiopathic arthritis. Arthritis Rheum 46(1):232–237CrossRefPubMed
47.
Wakil SM, Monies DM, Abouelhoda M et al (2015) Association of a mutation in LACC1 with a monogenic form of systemic juvenile idiopathic arthritis. Arthritis Rheumatol 67(1):288–295CrossRefPubMed
48.
Ombrello MJ, Remmers EF, Tachmazidou I et al (2015) HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. Proc Natl Acad Sci U S A 112(52):15970–15975CrossRefPubMedPubMedCentral
49.
Koeller M, Kiener H, Simonitsch I et al (1995) Destructive lymphadenopathy and T‑lymphocyte activation in adult-onset Still’s disease. Br J Rheumatol 34(10):984–988CrossRefPubMed
50.
Omoyinmi E, Hamaoui R, Pesenacker A et al (2012) Th1 and Th17 cell subpopulations are enriched in the peripheral blood of patients with systemic juvenile idiopathic arthritis. Rheumatology (Oxford) 51(10):1881–1886CrossRef
51.
Behrens EM, Beukelman T, Paessler M, Cron RQ (2007) Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 34(5):1133–1138PubMed
52.
Hadchouel M, Prieur AM, Griscelli C (1985) Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. J Pediatr 106(4):561–566CrossRefPubMed
53.
Sawhney S, Woo P, Murray KJ (2001) Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child 85(5):421–426CrossRefPubMedPubMedCentral
54.
Donn R, Ellison S, Lamb R, Day T, Baildam E, Ramanan AV (2008) Genetic loci contributing to hemophagocytic lymphohistiocytosis do not confer susceptibility to systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 58(3):869–874CrossRefPubMedPubMedCentral
55.
Zhang K, Biroschak J, Glass DN et al (2008) Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. Arthritis Rheum 58(9):2892–2896CrossRefPubMedPubMedCentral
56.
Vastert SJ, van Wijk R, D’Urbano LE et al (2010) Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. Rheumatology (Oxford) 49(3):441–449CrossRef
57.
Yanagimachi M, Goto H, Miyamae T et al (2011) Association of IRF5 polymorphisms with susceptibility to hemophagocytic lymphohistiocytosis in children. J Clin Immunol 31(6):946–951CrossRefPubMed
58.
Yanagimachi M, Naruto T, Miyamae T et al (2011) Association of IRF5 polymorphisms with susceptibility to macrophage activation syndrome in patients with juvenile idiopathic arthritis. J Rheumatol 38(4):769–774CrossRefPubMed
59.
60.
Quartier P (2010) Current treatments for juvenile idiopathic arthritis. Joint Bone Spine 77(6):511–516CrossRefPubMed
61.
DeWitt EM, Kimura Y, Beukelman T et al (2012) Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 64(7):1001–1010
62.
Kimura Y, DeWitt EM, Beukelman T et al (2014) Adding canakinumab to the Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans for systemic juvenile idiopathic arthritis: comment on the article by DeWitt et al. Arthritis Care Res (Hoboken) 66(9):1430–1431CrossRef
63.
Garcia-Carrasco M, Fuentes-Alexandro S, Escarcega RO, Rojas-Rodriguez J, Escobar LE (2007) Efficacy of thalidomide in systemic onset juvenile rheumatoid arthritis. Joint Bone Spine 74(5):500–503CrossRefPubMed
64.
Quartier P, Allantaz F, Cimaz R et al (2011) A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 70(5):747–754CrossRefPubMed
65.
Giampietro C, Ridene M, Lequerre T et al (2013) Anakinra in adult-onset Still’s disease: long-term treatment in patients resistant to conventional therapy. Arthritis Care Res (Hoboken) 65(5):822–826CrossRef
66.
Ortiz-Sanjuan F, Blanco R, Riancho-Zarrabeitia L et al (2015) Efficacy of Anakinra in refractory adult-onset still’s disease: multicenter study of 41 patients and literature review. Medicine (Baltimore) 94(39):e1554CrossRef
67.
Rossi-Semerano L, Fautrel B, Wendling D et al (2015) Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey. Orphanet J Rare Dis 10:19CrossRefPubMedPubMedCentral
68.
Ruperto N, Brunner HI, Quartier P et al (2012) Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 367(25):2396–2406CrossRefPubMed
69.
Ruperto N, Quartier P, Wulffraat N et al (2012) A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum 64(2):557–567CrossRefPubMed
70.
Goldbach-Mansky R, Shroff SD, Wilson M et al (2008) A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum 58(8):2432–2442CrossRefPubMedPubMedCentral
71.
Hashkes PJ, Spalding SJ, Giannini EH et al (2012) Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med 157(8):533–541CrossRefPubMed
72.
Hoffman HM, Throne ML, Amar NJ et al (2008) Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 58(8):2443–2452CrossRefPubMed
73.
Petryna O, Cush JJ, Efthimiou P (2012) IL-1 Trap rilonacept in refractory adult onset Still’s disease. Ann Rheum Dis 71(12):2056–2057CrossRefPubMed
74.
De Benedetti F, Brunner HI, Ruperto N et al (2012) Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 367(25):2385–2395CrossRefPubMed
75.
Yokota S, Miyamae T, Imagawa T et al (2005) Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 52(3):818–825CrossRefPubMed
76.
Yokota S, Miyamae T, Imagawa T, Katakura S, Kurosawa R, Mori M (2005) Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis. Clin Rev Allergy Immunol 28(3):231–238CrossRefPubMed
77.
Ortiz-Sanjuan F, Blanco R, Calvo-Rio V et al (2014) Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still’s disease: multicenter retrospective open-label study of thirty-four patients. Arthritis Rheumatol 66(6):1659–1665CrossRefPubMed
78.
Puechal X, DeBandt M, Berthelot JM et al (2011) Tocilizumab in refractory adult Still’s disease. Arthritis Care Res (Hoboken) 63(1):155–159CrossRef
79.
Al-Homood IA (2014) Biologic treatments for adult-onset Still’s disease. Rheumatology (Oxford) 53(1):32–38CrossRef
80.
Russo RA, Katsicas MM (2009) Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents. J Rheumatol 36(5):1078–1082CrossRefPubMed
81.
Quartuccio L, Maset M, De Vita S (2010) Efficacy of abatacept in a refractory case of adult-onset Still’s disease. Clin Exp Rheumatol 28(2):265–267PubMed
82.
Lee WS, Yoo WH (2014) Rituximab for refractory adult-onset Still’s disease with thrombotic microangiopathy. Rheumatology (Oxford) 53(9):1717–1718CrossRef
83.
Brinkman DM, de Kleer IM, ten Cate R et al (2007) Autologous stem cell transplantation in children with severe progressive systemic or polyarticular juvenile idiopathic arthritis: long-term follow-up of a prospective clinical trial. Arthritis Rheum 56(7):2410–2421CrossRefPubMed
84.
Brinkman DM, Jol-van der Zijde CM, ten Dam MM et al (2007) Resetting the adaptive immune system after autologous stem cell transplantation: lessons from responses to vaccines. J Clin Immunol 27(6):647–658CrossRefPubMedPubMedCentral
85.
Metadaten
Titel
Morbus Still im Kindes- und Erwachsenenalter
verfasst von
PD Dr. C. M. Hedrich
C. Günther
M. Aringer
Publikationsdatum
27.04.2017
Verlag
Springer Medizin
Erschienen in
Die Dermatologie / Ausgabe 6/2017
Print ISSN: 2731-7005
Elektronische ISSN: 2731-7013
DOI
https://doi.org/10.1007/s00105-017-3983-7

Weitere Artikel der Ausgabe 6/2017

Der Hautarzt 6/2017 Zur Ausgabe

Leitthema

Kontaktallergien der Kopfhaut

Leitthema

Psoriasis capitis und seborrhoisches Ekzem der Kopfhaut

Einführung zum Thema

Erkrankungen der Kopfhaut

Leitthema

Tropendermatologisch relevante Erkrankungen der Kopfhaut

Originalien

Erstmanifestation eines Ulcus cruris

Wie lautet Ihre Diagnose?

Schmerzhafte Schwellung und Einblutung beider Beine

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

16.04.2024 | Infektiologie | Nachrichten

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

12.04.2024 | Vitiligo | Nachrichten

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

12.04.2024 | Atopische Dermatitis | Nachrichten

Dupilumab ist mit kutanen T-Zell-Lymphomen assoziiert

09.04.2024 | DGP 2024 | Kongressbericht | Nachrichten

Chemotherapie mit Hindernissen
weitere anzeigen

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise